E 7130
Alternative Names: E-7130Latest Information Update: 12 Mar 2025
At a glance
- Originator Eisai Co Ltd
- Developer Eisai Co Ltd; Harvard University
- Class Antineoplastics
- Mechanism of Action Endothelial cell modulators; Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Breast cancer
Most Recent Events
- 27 Dec 2024 Eisai completes a phase-I trial in Solid tumours in Japan (IV, Injection) (NCT03444701)
- 23 Oct 2024 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 04 Aug 2023 E 7130 is still in phase I trials for Solid tumours in Japan (IV, Infusion) (Eisai pipeline, August 2023)